Biykem Bozkurt, MD, PhD, FACC, FAHA, FHFSA
Professor of Medicine
The Mary and Gordon Cain Chair &
W.A. "Tex" and Deborah Moncrief, Jr., Chair
Vice-Chair of Department of Medicine Baylor College of Medicine
Associate Director, Cardiovascular Research Institute
Director, Winters Center for Heart Failure Research
Baylor College of Medicine
Robert L Page II, PharmD, MSPH, BCPS (AQ-Cards), BCGP, FCCP, FASHP, FAHA, FHFSA
Professor, Department of Clinical Pharmacy
Clinical Specialist, Division of Cardiology
University of Colorado Anschutz Medical Campus
This activity will address the management of heart failure (HF) in older adults, African Americans, patients with diabetes, and patients with poor renal function.
Cardiologists, internists, pharmacists, NPs, PAs and other clinicians who encounter patients with HF.
Upon completion of this educational activity, the participant should be able to:
- Discuss the differences between HFrEF and HFpEF.
- Describe evidence-based recommendations for the management of chronic HFrEF.
- Incorporate guideline recommendations as appropriate for the management of special populations of patients including the elderly, African-Americans, patients with T2DM, and those with renal insufficiency.
Dr. Bozkurt discloses the following:
Consultant: Bristol-Myers Squibb, scPharmaceuticals, Inc., Lantheus Medical Imaging, Bayer HealthCare Pharmaceuticals, Respicardia, Abbott Vascular, Anthem, LivaNova
Dr. Page has no relevant conflicts of interest to disclose.
The planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of this continuing education activity hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. We are committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.
Purdue University requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.
In this educational activity, the faculty reports that their presentation will not contain reference to investigational and/or off-label uses.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Purdue University College of Pharmacy and MCM Education. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.
Purdue University designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Academy of PAs and the American Association of Nurse Practitioners accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge based, continuing education activity of Purdue University, an equal access/equal opportunity institution. Universal Activity Number (UAN): 0018-9999-19-039-H01-P; 1.0 contact hour (.10 CEU).
Commercial Support Statements
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
© 2019 MCM Education. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.